Search
Pasithea Therapeutics Corp
KTTAAdd to Watchlist
0.550USD
-0.017-3.02%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
13.71MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
1
analysts
Buy
Current Rating
3.000
Target Price
+470.23%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Pasithea Therapeutics Corp
KTTA
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Pasithea Therapeutics Corp's expected revenue for the next quarter?
Pasithea Therapeutics Corp's expected revenue is 300.00K.
How have Pasithea Therapeutics CorpKTTA's recent earnings per share performed?
The market expectation was USD -0.12, while Pasithea Therapeutics CorpKTTA's earnings per share (EPS) for the previous quarter was USD -0.79. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Pasithea Therapeutics Corp?
Based on the ratings of Pasithea Therapeutics Corp's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.